Thyroid complication models showed only moderate long-term validation in head and neck cancer
Existing thyroid complication models showed moderate performance and frequent miscalibration in long-term head and neck cancer survivorship.
Existing thyroid complication models showed moderate performance and frequent miscalibration in long-term head and neck cancer survivorship.
No radiation myelopathy was observed after target-prioritized intensity modulated radiotherapy for selected nasopharyngeal carcinoma near the spinal cord.
After 13 years, first-line temozolomide and radiotherapy produced similar progression-free and overall survival across molecularly classified low-grade gliomas.
Across 1,760 patients, most grade 3 adverse events remained below 1.5%, although post-prostatectomy urinary incontinence reached 10.2% by eight years.
A maximum left anterior descending coronary artery dose of at least 12 Gy was independently associated with higher long-term cardiac risk.
A nodal-to-primary tumor volume ratio of at least 15% was associated with lower three-year distant metastasis-free survival after extended-field radiotherapy.
A 40 Gy equivalent dose to at least 18% of the left anterior descending artery was associated with more than twofold risk of cardiac events.
Weekly cisplatin remained non-inferior to three-weekly cisplatin at five years in postoperative high-risk head and neck chemoradiotherapy.
ESTRO–ASTRO guidance supports selected rectal cancer reirradiation using 30–40 Gy regimens, cumulative dose assessment, inverse planning and daily volumetric imaging.
Commercial insurance, current smoking, single status, and neighborhood disadvantage were independently associated with radiotherapy-related debt sent to collections.
Induction chemotherapy showed no overall survival benefit, with outcomes differing by disease risk and the intensity of pre-radiotherapy treatment.
High-dose, high-linear-energy-transfer target coverage stratified local control after carbon-ion radiotherapy for adenoid cystic carcinoma.
Adding vaginal cuff brachytherapy to whole pelvis radiation therapy was associated with improved overall survival in stage II endometrioid endometrial cancer.